TRIM62 is downregulated in transition to ductal carcinoma in situ (DCIS) and becomes an independent predictor of local recurrence‐free survival (RFS) in early‐onset BC.168, 169. Here, TRIM62 is linked to ductal breast carcinoma in situ.